Quantcast

Latest congenital heart disease Stories

2010-07-08 07:34:00

ATLANTA, July 8 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that 2010 second quarter financial results will be released on Thursday, July 29, 2010. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive...

2010-07-06 13:53:14

Study shows gene-environment interaction in congenital heart disease A pregnant mother's diet may be able to interact with the genes her unborn child inherits and influence the type or severity of birth defect according to research funded by the Wellcome Trust and the British Heart Foundation (BHF). The study, published in the journal Human Molecular Genetics, suggests that mothers who eat a high fat diet before and through pregnancy could be inadvertently putting the health of their...

2010-06-30 07:04:00

ATLANTA, June 30 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that Medafor, Inc. is in the process of shipping approximately $2.1 million in HemoStase in accordance with the terms of the parties exclusive distribution agreement ("EDA"). On June 28, 2010 Medafor and CryoLife participated in a hearing with the District Court for the Northern District of Georgia, Atlanta...

2010-06-24 04:00:00

JENA, Germany, June 24, 2010 /PRNewswire/ -- In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent. AGA asked for permission to appeal to the...

2010-06-17 08:47:00

PHILADELPHIA, June 17 /PRNewswire-USNewswire/ -- Signaling a new frontier in the treatment of congenital heart disease (CHD), The Children's Hospital of Philadelphia is the first hospital in our region to implant transcatheter pulmonary heart valves in children with heart defects. This minimally invasive procedure gives patients a non-surgical option in their ongoing treatment. The Melody®( )Transcatheter Pulmonary Valve benefits patients with congenital heart defects...

2010-06-16 07:34:00

ATLANTA, June 16 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it will participate in the Sidoti & Company, LLC 2010 Semi Annual New York Micro-Cap Conference at The Grand Hyatt Hotel. Steven G. Anderson, president and chief executive officer of CryoLife, Inc., will present a corporate overview on Friday, June 25, 2010 at 10:00 a.m., Eastern Time. A copy of CryoLife's...

2010-06-08 07:34:00

ATLANTA, June 8 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) a biomaterials, medical device and tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoValve® SG pulmonary human heart valve processed with the Company's proprietary SynerGraft® technology. CryoLife's SynerGraft technology is designed to remove allogeneic donor cells and...

2010-06-07 07:34:00

ATLANTA, June 7 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company whose products include BioGlue Surgical Adhesive, announced today that it has completed the purchase of U.S. patent # 6,329,337. The patent involves the formulation and use of recombinant human serum albumin and gluteraldehyde, and now becomes part of CryoLife's protein hydrogel patent portfolio, which includes BioGlue. "CryoLife will...

2010-06-03 09:00:00

LINCOLNSHIRE, Ill., June 3 /PRNewswire/ -- A congenital heart defect survivor is pedaling his bike across America, beginning June 8, 2010, to raise awareness about congenital heart defects and raise $100,000 in research dollars for the Children's Heart Foundation (CHF). To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/childrensheartfoundation/44443/ (Photo: http://www.newscom.com/cgi-bin/prnh/20100603/MM14402) "BIKE 4 CHF" --...

2010-06-01 07:06:00

ATLANTA, June 1 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that its Board of Directors has authorized the purchase of up to $15 million of its common stock over the course of the next two years, beginning no earlier than June 2, 2010. The purchase of shares will be made from time to time in the open market or through privately negotiated transactions on such terms as management...


Latest congenital heart disease Reference Libraries

Echocardiogram
2013-07-29 11:11:00

An echocardiogram is a test that, much like an ultrasound, uses sound waves to create a moving image of the heart. The most common type of echocardiogram is performed transthoracic, meaning the image is taken through a probe against the chest. A TTE does not involve radiation and is a very safe procedure. A cardiac sonographer will put a gel on the patient's chest and move the transducer around different areas, including directly anterior to the breastbone, inferior and lateral to the right...

More Articles (1 articles) »
Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.